New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma’s VP3 Nasal Spray SystemCrystal Lake, Illinois, January 27, 2022 - Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, today announced that its VP3 multido.
Glenmark Pharma launches nasal spray Ryaltris in India
SECTIONS
Last Updated: May 03, 2021, 11:25 AM IST
Share
Synopsis
Glenmark being one of the leaders in respiratory segment, has been the first to launch the branded generic version at an affordable cost for the treatment of allergic rhinitis in India.
Agencies
Glenmark Pharma on Monday announced of launch its nasal spray Ryaltris, used for treatment of moderate to severe allergic rhinitis, in India.
Glenmark being one of the leaders in respiratory segment, has been the first to launch the branded generic version at an affordable cost for the treatment of allergic rhinitis in India. This will provide patients a far more convenient, cost effective treatment option in the country, Glenmark said in a regulatory filing.